Kidney Cancer Development Program at DF/HCC
Official title: DF/HCC Kidney Cancer Development Research Program (DRP)
Funded at Beth Israel Deaconess Medical Center · NIH-11421801 · Data updated 2026-11-12
A funded program at Dana-Farber/Brigham and Women’s Kidney Cancer Center supports new ideas from researchers to improve understanding and treatment of kidney cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 18, 2003 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $322,233 |
| NIH project number | 2P50CA101942-21A1 |
| Project ID | NIH-11421801 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are researchers with promising kidney cancer ideas who could evolve their work into patient-focused studies.
✕Less likely to help
Patients not involved in sponsored developmental projects or unrelated to kidney cancer may not directly benefit.
What this research studies
This NIH grant funds developmental, high-potential kidney cancer projects that complement the DF/HCC Kidney Cancer SPORE. It aims to nurture innovative ideas and involve more junior investigators, leveraging the program’s infrastructure for soliciting, evaluating, funding, and transitioning projects into full studies. The focus is on advancing kidney cancer research with the possibility of translating promising work into broader efforts for patients. The program is anchored at Beth Israel Deaconess Medical Center in Boston under the leadership of Dr. David McDermott.
Why it matters
Potential benefit: If successful, the program could accelerate new insights and treatments for kidney cancer that benefit patients in the DF/HCC network and beyond.
How similar studies have gone: Developmental projects in cancer centers have historically seeded later-stage research that improves patient care, though outcomes depend on subsequent transition to full studies.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Mcdermott, David — Beth Israel Deaconess Medical Center
- Study coordinator: Mcdermott, David
Related research
Other NIH-funded projects on the same topics.
-
Maximizing anti-tumor immune responses in kidney cancer
A cutting-edge program at UT Southwestern aims to speed up better immunotherapy options for kidney cancer by studying how to activate both innate and adaptive immune responses.
-
Kidney Cancer Career Enhancement Program (CEP) at DF/HCC
A career-boosting program supports junior investigators studying kidney cancer to help them advance in basic, translational, and clinical work.
-
Personalized antigens for kidney cancer therapy
This grant explores identifying and targeting tumor-specific antigens in kidney cancer to develop more effective, personalized immunotherapies.
-
Optimizing Anti-PD1 Therapy for High-Risk and Metastatic Kidney Cancer
A large cancer research grant is testing how best to use anti-PD-1 therapy to help people with high-risk and metastatic kidney cancer live longer and with fewer side effects.
-
Targeting the HIF2 Pathway in Kidney Cancer
A cancer treatment program aims to see if a drug called belzutifan can help people with a specific kind of kidney cancer whose growth is driven by the HIF2 pathway.
-
Kidney Cancer Tissue Bank and Data Repository Core
A kidney cancer tissue, blood and clinical data repository core aims to collect, store, and organize samples and linked clinical information to support research and improve care for kidney cancer patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.